Ornidazole PCD Pharma Franchise Company
Cafoli Lifecare is a trusted Ornidazole PCD pharma franchise company in India, offering 16 Ornidazole formulations across tablets, injection, suspension and cream, including the fast-moving fixed-dose combinations that dominate the Indian anti-infective market. All products are manufactured at WHO-GMP certified, DCGI-approved facilities and offered with exclusive district-wise monopoly rights.
What is Ornidazole?
Ornidazole is a 5-nitroimidazole antimicrobial active against anaerobic bacteria and protozoa. Inside these organisms, its nitro group is reduced to reactive intermediates that bind and fragment microbial DNA, causing cell death. Because the reduction step requires the low-redox environment found only in anaerobes and protozoa, its action is selective for those pathogens. It is used in amoebiasis, giardiasis, trichomoniasis, bacterial vaginosis and anaerobic bacterial infections, and is frequently combined with an aerobic-spectrum antibiotic. Compound data is available on PubChem.
Available Ornidazole Formulations
The Cafoli Lifecare Ornidazole range comprises 16 formulations in the following dosage forms:
- Tablets
- Injection
- Suspension
- Cream
Brand names, compositions, pack sizes and net rates are shared with registered franchise enquiries. Contact our team for the current Ornidazole price list.
Therapeutic Applications of Ornidazole
Prescribed under medical supervision for:
- Intestinal and hepatic amoebiasis
- Giardiasis
- Trichomoniasis and bacterial vaginosis
- Infective diarrhoea and mixed aerobic-anaerobic gastrointestinal infection
- Anaerobic infections in dental, surgical and gynaecological practice
- Prophylaxis of post-operative anaerobic infection
Prescriber specialties: gastroenterologists, consulting physicians, gynaecologists, dentists, surgeons and paediatricians. Ornidazole is a prescription-only anti-infective and should be used in line with antimicrobial stewardship guidance.
Why Ornidazole is a High-Potential Molecule for Distributors
Ornidazole's commercial position rests on a clinical fact: most of the infections Indian doctors see every day are mixed, not purely aerobic. Amoebiasis, giardiasis and infective diarrhoea remain endemic across the country and spike sharply each monsoon, and pelvic, dental and intra-abdominal infections routinely involve anaerobes. Ornidazole is the standard answer to that anaerobic and protozoal half of the picture, which is why the Ofloxacin-Ornidazole combination has become one of the single largest anti-infective categories in Indian pharma by volume. For a franchise partner this delivers three things at once: very high underlying prescription volume, a genuinely multi-speciality prescriber base spanning gastro, gynae, dental and surgery, and fast stock turns because acute infection prescriptions are dispensed the same day. The presence of injection and suspension alongside tablets extends the same allotment into nursing homes and paediatric practice.
Why Choose Cafoli Lifecare
- Monopoly rights — exclusive district-wise marketing rights across all 16 Ornidazole formulations
- WHO-GMP certified manufacturing and DCGI-approved products
- Promotional inputs — visual aids, MR bags, prescription pads, samples and reminder cards
- 1000+ franchise partners across India with an on-time dispatch record
- Transparent net rates and dedicated franchise support
References
- PubChem — Ornidazole compound record
- PubMed — Ornidazole in amoebiasis and giardiasis
- WHO Model List of Essential Medicines
Our formulations of Ornidazole find application in many critical therapeutic areas. Its therapeutic spectrum includes, but is not limited to: